Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,292 papers from all fields of science
Search
Sign In
Create Free Account
Tetravalent Meningococcal Vaccine
Known as:
Meningococcal Vaccine, Tetravalent
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Meningococcal vaccine
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype
Stefan W. Metz
,
A. Thomas
,
+8 authors
A. D. de Silva
PLoS Neglected Tropical Diseases
2018
Corpus ID: 52813415
Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic shock syndrome. Dengue vaccine development is…
Expand
2016
2016
[Effect of High Council for Public Health on September 28th 2012 recommendation about antipapillomavirus vaccination on antipapillomavirus and trivalent or tetravalent DTP or DTCP co-vaccination in…
J. Birebent
,
Julie Dupouy
,
C. Roussel
,
R. Bourrel
,
M. Bismuth
,
S. Oustric
The´rapie (Paris)
2016
Corpus ID: 205359323
Review
2015
Review
2015
Protective Immune Responses to Dengue Virus Infection and Vaccines: Perspectives from the Field to the Bench
S. Halstead
,
S. Zompi
Frontiers in Immunology
2015
Corpus ID: 20657752
Dengue research is in turmoil following confusing efficacy reports from large-scale phase III clinical studies on the lead…
Expand
Review
2014
Review
2014
Human Immune Responses to Dengue Virus Infection: Lessons Learned from Prospective Cohort Studies
T. Endy
Frontiers in Immunology
2014
Corpus ID: 2218041
Dengue virus (DENV) continues to spread globally and is a major cause of morbidity and mortality. Currently, there is no…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE